A detailed history of Truist Financial Corp transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Truist Financial Corp holds 10,900 shares of IBRX stock, worth $23,217. This represents 0.0% of its overall portfolio holdings.

Number of Shares
10,900
Holding current value
$23,217
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 03, 2025

BUY
$2.24 - $3.01 $24,416 - $32,809
10,900 New
10,900 $26,000

Others Institutions Holding IBRX

About ImmunityBio, Inc.


  • Ticker IBRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 400,304,000
  • Market Cap $853M
  • Description
  • ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...
More about IBRX
Track This Portfolio

Track Truist Financial Corp Portfolio

Follow Truist Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

News

Stay updated on Truist Financial Corp with notifications on news.